Prosthetic Joint Infections of Hip clinical trials at UCLA
1 in progress, 0 open to eligible people
TRL1068 for the Treatment of Prosthetic Joint Infection
Sorry, not currently recruiting here
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
Los Angeles, California and other locations
Our lead scientists for Prosthetic Joint Infections of Hip research studies include Alexandra Stavrakis, MD.
Last updated: